This page is available in multiple languages
Select Language

Ikonisys lists on Euronext Growth Paris

Back

  • €4.0 million raised – market capitalisation of €55 million
  • Listing brings number of MedTech companies listed on Euronext to 46

Paris – 19 July 2021 – Euronext today congratulates Ikonisys, a MedTech specialising in cellular diagnosis, on its listing on Euronext Growth Paris (ticker code: ALIKO).

Based in the United States, in France and in Italy, Ikonisys specialises in the early and accurate detection of cancerous diseases through a unique solution, a fully-automated digital fluorescence microscope. Ikonisys uses a combination of equipment, software and reagents to deliver automated diagnoses, with the aim of improving the communication of the results of analysis by medical laboratories. The company is going public today to accelerate the development of its platform Ikoniscope20® in the US and in Europe, while also aiming to develop new innovative applications based on artificial intelligence.

Ikonisys was listed through the admission to trading of the 9,481,727 shares making up its equity, of which 700,000 new shares were issued under a Global Offering[1].

The admission and issue price of Ikonisys shares was set at €5.75 per share. Market capitalisation was €54.5 million on the day of listing. The offering raised €4 million altogether.

Mario Crovetto, CEO of Ikonisys, said: “I would like to thank all the shareholders, both private and institutional, who have shown their confidence in us by contributing to the success of this IPO. I would also like to warmly thank our employees and customers, who, through their involvement and trust, make Ikonisys successful on a daily basis. Ikonisys has just taken a major step in its development by going public on Euronext Growth Paris. We will be able to benefit from the richness of the French MedTech ecosystem, one of the most dynamic in the world. This round of financing will enable us to accelerate our development and, in particular, the marketing in the United States and Europe of our new platform, the Ikoniscope20, a state-of-the-art digital microscope for the automated identification of circulating tumour cells (CTCs). These new financial resources will also support continued R&D funding to maintain the technological leadership of our platform. As you can see, the Ikonisys adventure is just beginning, and we start a new chapter in its history today.”

Ikonisys 20210719

Caption: Mario Crovetto, CEO of Ikonisys, and his team rang the bell during a virtual ceremony this morning together with Camille Leca, Head of Listing France at Euronext, to celebrate the Initial Public Offering of Ikonisys.

[1] The Global Offering was made up of a Public Offering that included an Open Price Public Offering and a Global Placement with institutional investors in France and other countries.

About Ikonisys

Ikonisys is a privately held cell-based diagnostics company based in New Haven, Connecticut (USA) and Milan, Italy. The company develops, produces and markets the proprietary Ikoniscope20® platform, designed to deliver highly accurate and reliable detection of rare cells. Utilising advanced molecular and immunological markers, Ikoniscope-built applications are used extensively in the US and Europe for the diagnosis of a variety of cancers. Ikonisys has received FDA clearance for several automated diagnostic applications also marketed in Europe under CE certification. More information at www.ikonisys.com

Press Release Footer

About Euronext 
Euronext is the leading pan-European market infrastructure, connecting local economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. With close to 1,900 listed issuers and around €6.4 trillion in market capitalisation as of end June 2021, it has an unmatched blue chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets, one of Europe’s leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates a number of junior markets, simplifying access to listing for SMEs. Euronext provides custody and settlement services through central securities depositories in Denmark, Italy, Norway and Portugal. 
For the latest news, follow us on Twitter (twitter.com/euronext) and LinkedIn (linkedin.com/euronext).

Disclaimer
This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at www.euronext.com/terms-use.

© 2021, Euronext N.V. - All rights reserved.